Prodeon Medical’s BPH Implant Gains FDA Clearance

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

FDA cleared Urocross, a non-permanent BPH implant. It remodels tissue for 6 months, then is intentionally retrieved, leaving no permanent implant behind....

Prodeon Medical’s BPH implant gains FDA clearance

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.The post Prodeon Medical’s BPH implant gains FDA clearance appeared first on Medical Device Network.